Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks Therapeutics. Under the deal, Merck will pay $47 per share in ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China. The estimate doesn’t account for the possibility that ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.

The company's key drug, Gardasil, is facing slowing sales in China. Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly beat ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF ...

We believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock. MRK stock trades at 14x forward earnings, versus 20x for ABBV. We think this gap ...

RAHWAY, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused ...

Merck made the biopharma industry’s second-largest deal of 2021 when it acquired Acceleron for $11.5 billion. Last year, Merck’s $10.8 billion buyout of Prometheus was the third-largest in the ...

Merck & Co. has secured a seat at the productive Daiichi Sankyo antibody-drug conjugate (ADC) factory. While AstraZeneca picked up the first two ADCs off the production line, its rival and ...

Merck's crown jewel, Keytruda, is still the star of the show. There are other pieces to the company's business. Merck is actively looking to diversify its source of sales. Perhaps Merck is dealing ...